Dr. Postow on Combination Regimens for High-Risk Melanoma

(1:17)

Dr. Postow on Entrectinib in Melanoma

(1:16)

Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell Carcinoma

(33)

Dr. Postow on FDA Approval of Adjuvant Dabrafenib Plus Trametinib in BRAF-Mutant Melanoma

(30)

Dr. Postow Discusses Combination Therapy for Melanoma

(1:17)

Dr. Postow on Immunotherapy Advancements in Melanoma

(1:17)

Oncologist-to-Oncologist: How to Treat Your Patients with Immunotherapy

(55:22)

TIL Therapy for Advanced Melanoma

(27:55)

Getting Vitamin D from the Sun WITHOUT the Skin Cancer

(9:17)

Understanding COPD

(4:36)

ASCO 2024: Advances in Melanoma and Related Cancers

(1:2:27)

Cancer Immunotherapy - PD-1 and PD-L1

(4:)

Sinusitis, Animation.

(3:8)

IMMUNOTHERAPY: The Path to a Cancer Cure (For Clinicians)

(8:42)

How to Make the Most of Stage IV Decision Making for Patients and Caregivers

(36:38)

The Latest Treatments for Melanoma - An Overview

(25:44)

The Sun Doesn't Cause Skin Cancer, But Sunscreen Does!

(6:7)

Dr. Postow on the Current Treatment Landscape in Melanoma

(1:18)

Ask the Expert - My Melanoma Therapy Stopped Working: What's Next?

(57:55)

Dr. Postow on BRAF and MEK Inhibitor Combination Studies in Melanoma

(1:19)

Dr. Postow on OS Results of CheckMate-069 Study

(57)

Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma

(1:15)

Dr. Postow on Advancements of Immunotherapy in Melanoma

(1:20)

New Checkpoint Inhibitors \u0026 Immunotherapy in Metastatic Melanoma - Michael Postow MD

(23:20)

Dr. Michael A. Postow on the Treatment of Melanoma-Related Toxicities

(1:8)

Dr. Postow on Using PD-L1 as a Biomarker of Response

(1:14)

Evaluating the Use of Immune Checkpoint Inhibitors in Melanoma

(14:32)

2013 OncPrac Summit: Michael Postow on immuno- and targeted therapies for melanoma

(5:29)

Michael A. Postow, MD - Immunomodulatory Strategies

(51:47)